Prodromal bullous pemphigoid

International Journal of Dermatology

Volumn 45, Issue 3, 2006, Pages 209-214

  Lamb, Philina M ^a,b,c,d   Abell, Edward ^a,b,c,d   Tharp, Michael ^a,b,c,d   Frye, Roy ^a,b,c,d   Deng, Jau Shyong ^a,b,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Rabkin Dermatopathology Laboratory   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; CORTICOSTEROID; DOXYCYCLINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TETRACYCLINE;

ADULT; AGED; CLINICAL FEATURE; COHORT ANALYSIS; DERMATITIS HERPETIFORMIS; DISEASE DURATION; ECZEMA; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PEMPHIGOID; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; URTICARIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMPLEMENT C3; DOXYCYCLINE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; TETRACYCLINE;

EID: 33644761912     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02457.x     Document Type: Review

References (33)

1. Bean SF, Micehl B, Furey N, et al. Vesicular pemphigoid. Arch Dermatol 1976; 112: 1402-1404.
2. Asbrink E, Hovmark A. Clinical variations in bullous pemphigoid with respect to early symptoms. Acta Dermatol Venereol (Stockh) 1981; 61: 417-421.
3. Korman NJ. Bullous pemphigoid. Arch Dermatol 1998; 134: 1137-1141.
4. Alonso-Llamazares J, Rogers RS III, Oursler JR, et al. Bullous pemphigoid presenting as generalized pruritus: Observations in six patients. Int J Dermatol 1998; 37: 508-514.
5. Barker DJ. Generalized pruritus as the presenting feature of bullous pemphigoid. Br J Dermatol 1983; 109: 237-238.
6. Strohal R, Rappersberger K, Pehamberger H, et al. Nonbullous pemphigoid. Prodrome of bullous pemphigoid or a distinct pemphigoid variant? J Am Acad Dermatol 1993; 29: 293-299.
7. Wolf R, Ophir J, Dechner E. Nonbullous bullous pemphigoid. In J Dermatol 1992; 31: 498-500.
8. Amato DA, Silverstein J, Zitelli J. The prodrome of bullous pemphigoid. Int J Dermatol 1988; 27: 560-563.
9. Levine N, Freilich A, Barland P. Localized pemphigoid simulating dyshidrosiform dermatitis. Arch Dermatol 1979; 115: 320-321.
10. Rongioletti F, Parodi A, Rebora A. Dyshidrosiform pemphigoid: Report of an additional case. Dermatologica 1985; 170: 84-85.
11. Yung CW, Soltani K, Lorincz AL. Pemphigoid nodularis. J Am Acad Dermatol 1981; 5: 54-60.
12. Tani M, Murata Y, Masaki H. Pemphigoid nodularis. J Am Acad Dermatol 1989; 21: 1099-1104.
13. Winkelmann RK, Su WPD. Pemphigoid vegetans. Arch Dermatol 1979; 115: 446-448.
14. Kuokkanen K, Helin H. Pemphigoid vegetans. Arch Dermatol 1981; 117: 56-57.
15. Alonso-Llamazares J, Dietrich SM, Gibson LE. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol 1998; 39: 827-830.
16. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995; 133: 967-971.
17. Saitoh A, Osada A, Ohtake N, et al. Erythrodermic bullous pemphigoid. J Am Acad Dermatol 1993; 28: 124-125.
18. Tappeiner G, Konrad K, Holubar K. Erythrodermic bullous pemphigoid: report of a case. J Am Acad Dermatol 1982; 6: 489-492.
19. Ruiz E, Deng JS, Abell EA. Eosinophilic spongiosis: A clinical, histologic, and immunopathologic study. J Am Acad Dermatol 1994; 30: 973-976.
20. Crotty C, Pittelkow M, Muller SA. Eosinophilic spongiosis: A clinicopathologic review of seventy-one cases. J Am Acad Dermatol 1983; 8: 337-343.
21. Roujeau J, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-469.
22. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 2002; 138: 903-908.
23. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979; 101: 521-534.
24. Joly P, Roujeau J, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-327.
25. Bystryn J-C, Wainwright BD, Shupack JL. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med 2002; 347: 143-145 (discussion 143-144).
26. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986; 122: 670-674.
27. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997; 36: 101-103.
28. Stern RS. Bullous pemphigoid therapy - think globally, act locally. N Engl J Med 2002; 346: 364-367.
29. Korman NJ. New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clinics 2001; 19: 637-648.
30. Khumalo NP, Murrell DF, Wojnarowska F, et al. A systemic review of treatments for bullous pemphigoid. Arch Dermatol 2002; 138: 385-389.
31. Bernard P, Bedane C, Bonnetblanc J-M. Anti-BP180 autoantibodies as a marker for poor prognosis in bullous pemphigoid: A cohort analysis of 94 elderly patients. Br J Dermatol 1997; 136: 694-698.
32. Asbrink E, Hovmark A. Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies. Acta Derm Venereol (Stockh) 1984; 64: 243-246.
33. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26: 585-589.